2024 Q4 Form 10-Q Financial Statement
#000155837024015537 Filed on November 13, 2024
Income Statement
Concept | 2024 Q4 | 2024 Q3 | 2023 Q3 |
---|---|---|---|
Revenue | $0.00 | ||
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $4.520M | ||
YoY Change | 17.57% | ||
% of Gross Profit | |||
Research & Development | $1.715M | $5.292M | |
YoY Change | -67.58% | 7.49% | |
% of Gross Profit | |||
Depreciation & Amortization | $8.130K | $42.75K | |
YoY Change | -80.98% | -9.72% | |
% of Gross Profit | |||
Operating Expenses | $11.23M | $9.813M | |
YoY Change | 14.47% | 11.93% | |
Operating Profit | -$11.23M | -$9.813M | |
YoY Change | 14.47% | 11.93% | |
Interest Expense | $184.5K | $611.0K | |
YoY Change | -69.8% | 150.82% | |
% of Operating Profit | |||
Other Income/Expense, Net | $1.409M | $611.0K | |
YoY Change | 130.69% | ||
Pretax Income | -$9.200M | ||
YoY Change | 7.93% | ||
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$9.824M | -$9.203M | |
YoY Change | 6.76% | 7.96% | |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$0.15 | -$0.14 | |
Diluted Earnings Per Share | -$0.15 | -$0.14 | |
COMMON SHARES | |||
Basic Shares Outstanding | 64.48M | 64.48M | 64.32M |
Diluted Shares Outstanding | 64.48M | 64.35M |
Balance Sheet
Concept | 2024 Q4 | 2024 Q3 | 2023 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $14.39M | $49.40M | |
YoY Change | -70.87% | -4.31% | |
Cash & Equivalents | $14.40M | $49.41M | |
Short-Term Investments | |||
Other Short-Term Assets | $1.204M | $2.400M | |
YoY Change | -49.84% | 12.51% | |
Inventory | |||
Prepaid Expenses | $798.3K | $1.811M | |
Receivables | |||
Other Receivables | $50.26K | $188.9K | |
Total Short-Term Assets | $15.65M | $52.01M | |
YoY Change | -69.92% | -3.41% | |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $0.00 | $133.0K | |
YoY Change | -100.0% | -53.84% | |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $52.32K | $100.0K | |
YoY Change | -47.68% | -88.37% | |
Total Long-Term Assets | $52.32K | $1.191M | |
YoY Change | -95.61% | -43.66% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $15.65M | $52.01M | |
Total Long-Term Assets | $52.32K | $1.191M | |
Total Assets | $15.70M | $53.20M | |
YoY Change | -70.49% | -4.93% | |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $581.8K | $329.9K | |
YoY Change | 76.36% | -61.29% | |
Accrued Expenses | $3.478M | $5.311M | |
YoY Change | -34.52% | -8.61% | |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $4.322M | $6.391M | |
YoY Change | -32.37% | -17.52% | |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Other Long-Term Liabilities | $0.00 | $300.0K | |
YoY Change | -100.0% | 213.77% | |
Total Long-Term Liabilities | $0.00 | $300.0K | |
YoY Change | -100.0% | 213.77% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $4.322M | $6.391M | |
Total Long-Term Liabilities | $0.00 | $300.0K | |
Total Liabilities | $4.322M | $6.653M | |
YoY Change | -35.04% | -15.18% | |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$487.1M | -$447.4M | |
YoY Change | 8.88% | 9.3% | |
Common Stock | $64.48K | $64.37K | |
YoY Change | 0.18% | 22.79% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $11.38M | $46.55M | |
YoY Change | |||
Total Liabilities & Shareholders Equity | $15.70M | $53.20M | |
YoY Change | -70.49% | -4.93% |
Cashflow Statement
Concept | 2024 Q4 | 2024 Q3 | 2023 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$9.824M | -$9.203M | |
YoY Change | 6.76% | 7.96% | |
Depreciation, Depletion And Amortization | $8.130K | $42.75K | |
YoY Change | -80.98% | -9.72% | |
Cash From Operating Activities | -$7.994M | -$8.680M | |
YoY Change | -7.9% | 0.73% | |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | $10.00K | |
YoY Change | -100.0% | -503.23% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | $0.00 | -$10.00K | |
YoY Change | -100.0% | 303.23% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | 60.00K | |
YoY Change | -100.0% | ||
NET CHANGE | |||
Cash From Operating Activities | -7.994M | -8.680M | |
Cash From Investing Activities | 0.000 | -10.00K | |
Cash From Financing Activities | 0.000 | 60.00K | |
Net Change In Cash | -7.994M | -8.630M | |
YoY Change | -7.37% | 0.12% | |
FREE CASH FLOW | |||
Cash From Operating Activities | -$7.994M | -$8.680M | |
Capital Expenditures | $0.00 | $10.00K | |
Free Cash Flow | -$7.994M | -$8.690M | |
YoY Change | -8.0% | 0.87% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2024Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001253689 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2024Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2024Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
64483958 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
64393744 | |
us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | ||
CY2024Q3 | glyc |
Lessee Operating Lease Liability Payments Due After Year Two
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
|
||
CY2024Q3 | us-gaap |
Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-36177 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
GlycoMimetics, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
06-1686563 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9708 Medical Center Drive | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Rockville | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20850 | ||
dei |
City Area Code
CityAreaCode
|
240 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
243-1201 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value | ||
dei |
Trading Symbol
TradingSymbol
|
GLYC | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2024Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
64483958 | |
CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14391664 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
41792830 | |
CY2024Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1254157 | |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1997904 | |
CY2024Q3 | us-gaap |
Assets Current
AssetsCurrent
|
15645821 | |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
43790734 | |
CY2023Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
603737 | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
767828 | |
CY2024Q3 | us-gaap |
Other Assets
OtherAssets
|
52320 | |
CY2023Q4 | us-gaap |
Other Assets
OtherAssets
|
154176 | |
CY2024Q3 | us-gaap |
Assets
Assets
|
15698141 | |
CY2023Q4 | us-gaap |
Assets
Assets
|
45316475 | |
CY2024Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
581794 | |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
868115 | |
CY2024Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3477929 | |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5225557 | |
CY2024Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
262133 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
741558 | |
CY2024Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4321856 | |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
6835230 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
66844 | |
CY2024Q3 | us-gaap |
Liabilities
Liabilities
|
4321856 | |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
6902074 | |
CY2024Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2024Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2024Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2024Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2024Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2024Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
64483958 | |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
64393744 | |
CY2024Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
64484 | |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
64394 | |
CY2024Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
498453419 | |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
494835219 | |
CY2024Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-487141618 | |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-456485212 | |
CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11376285 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
38414401 | |
CY2024Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
15698141 | |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
45316475 | |
CY2024Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1715347 | |
CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5291790 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14026542 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14783204 | ||
CY2024Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4005857 | |
CY2023Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4521706 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13167383 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
14901255 | ||
CY2024Q3 | us-gaap |
Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
|
5512594 | |
us-gaap |
Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
|
5512594 | ||
CY2024Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
11233798 | |
CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
9813496 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
32706519 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
29684459 | ||
CY2024Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11233798 | |
CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9813496 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32706519 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-29684459 | ||
CY2024Q3 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
1224945 | |
us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
1224945 | ||
CY2024Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
184520 | |
CY2023Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
610978 | |
us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
825168 | ||
us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1863679 | ||
CY2024Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1409465 | |
CY2023Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
610978 | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2050113 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1863679 | ||
CY2024Q3 | glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-9824333 | |
CY2023Q3 | glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-9202518 | |
glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-30656406 | ||
glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-27820780 | ||
CY2024Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.15 | |
CY2024Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.15 | |
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.14 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.14 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.48 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.48 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.44 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.44 | ||
CY2024Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
64483958 | |
CY2024Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
64483958 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
64349709 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
64349709 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
64475013 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
64475013 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
62992006 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62992006 | ||
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
38414401 | |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
36000 | |
CY2024Q1 | glyc |
Stock Issued During Period Value Stock Options And Warrants And Restricted Stock Units Vesting
StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting
|
4898 | |
CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1192080 | |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10736667 | |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
28910712 | |
CY2024Q2 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
39375 | |
CY2024Q2 | glyc |
Stock Issued During Period Value Stock Options And Warrants And Restricted Stock Units Vesting
StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting
|
500 | |
CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1207322 | |
CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10095406 | |
CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20062503 | |
CY2024Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1138115 | |
CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9824333 | |
CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11376285 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
42929837 | |
CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
28707011 | |
CY2023Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
33768 | |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
870180 | |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10359350 | |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
62181446 | |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
20114 | |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
858088 | |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8258912 | |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
54800736 | |
CY2023Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
61616 | |
CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
887837 | |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9202518 | |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
46547671 | |
us-gaap |
Profit Loss
ProfitLoss
|
-30656406 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-27820780 | ||
us-gaap |
Depreciation
Depreciation
|
35174 | ||
us-gaap |
Depreciation
Depreciation
|
130004 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-76654 | ||
us-gaap |
Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
|
365179 | ||
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
402649 | ||
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
668756 | ||
us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
75375 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3537517 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2616105 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-743747 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-241640 | ||
glyc |
Increase Decrease In Prepaid Research And Development Expenses
IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses
|
-603737 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-286321 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-640306 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1747628 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1680629 | ||
glyc |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-546269 | ||
glyc |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-779696 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27396592 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27264906 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
9972 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
20593 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-9972 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-20593 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
28707011 | ||
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
5398 | ||
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
115498 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5398 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
28822509 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-27401166 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
1537010 | ||
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
41792830 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
47870619 | |
CY2024Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
14391664 | |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
49407629 | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The Company was previously developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. In July 2024, following feedback from the U.S. Food and Drug Administration (FDA), the Company determined that the regulatory path forward for its lead product candidate, uproleselan, for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. The decision to not conduct an additional clinical trial did not relate to any safety or medical issues or negative regulatory feedback related to the Company’s programs. In order to conserve its cash resources, in July 2024 the Company reduced its workforce by approximately </span>80%<span style="white-space:pre-wrap;">. The Company also initiated a strategic review of its business in an effort to maximize shareholder value. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Following the strategic review on October 28, 2024 the Company entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Crescent Biopharma, Inc., a Delaware corporation (Crescent), pursuant to which Crescent will become a wholly owned subsidiary of the Company (the Merger). Upon completion of the Merger, the Company plans to operate under the name Crescent Biopharma, Inc. The Merger is expected to close in the second quarter of 2025, subject to certain closing conditions, including, among other things, approval by the stockholders of each company and the satisfaction of customary closing conditions. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended. Pursuant to the exchange ratio formula set forth in the Merger Agreement, upon the closing of the Merger (but prior to closing of the Private Placement described below), on a pro forma basis and based upon the number of shares of common stock of the Company expected to be issued in the Merger, pre-Merger Crescent stockholders will own approximately 86.2% of the combined company and pre-Merger stockholders of the Company will own approximately 13.8% of the combined company. After giving further effect to the Private Placement, the pre-Merger Crescent stockholders (inclusive of those investors participating in the Private Placement) are expected to own approximately 96.9% of the combined company and the pre-Merger stockholders of the Company are expected to own approximately 3.1% of the combined company. The exchange ratio will be adjusted to the extent that the Company’s net cash at closing of the Merger is less than $1.0 million and will be based on the amount of proceeds actually received by the Company in the Private Placement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors have entered into a securities purchase agreement (the Purchase Agreement) with the Company, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase, immediately following the consummation of the Merger, shares of the Company’s common stock and pre-funded warrants (together, the PIPE Securities) for an aggregate purchase price of approximately $200.0 million in a private placement (the Private Placement). The closing of the Private Placement is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement (in addition to other customary closing conditions) and is expected to occur immediately following the closing of the Merger.</p> | ||
CY2024Q3 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
|
0.80 | |
CY2024Q4 | glyc |
Merger Agreement Exchange Ratio Determination Maximum Net Cash At Closing
MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing
|
1000000.0 | |
glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-30700000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27400000 | ||
CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14400000 | |
CY2024Q3 | us-gaap |
Severance Costs1
SeveranceCosts1
|
5000000.0 | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. </p> | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | ||
CY2024Q3 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
798274 | |
CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1420642 | |
CY2024Q3 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
405628 | |
CY2023Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
401442 | |
CY2024Q3 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
50255 | |
CY2023Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
175820 | |
CY2024Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1254157 | |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1997904 | |
CY2024Q3 | glyc |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
758599 | |
CY2023Q4 | glyc |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
1824689 | |
CY2023Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
2561913 | |
CY2024Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
473770 | |
CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
439192 | |
CY2024Q3 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
439130 | |
CY2023Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
302778 | |
CY2024Q3 | glyc |
Accrued Retention Current
AccruedRetentionCurrent
|
427908 | |
CY2024Q3 | glyc |
Accrued Severance Current
AccruedSeveranceCurrent
|
1378522 | |
CY2023Q4 | glyc |
Accrued Severance Current
AccruedSeveranceCurrent
|
96985 | |
CY2024Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3477929 | |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5225557 | |
CY2024Q3 | us-gaap |
Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
|
true | |
CY2023Q2 | us-gaap |
Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
|
400000 | |
glyc |
Lessee Operating Lease Number Of New Leases
LesseeOperatingLeaseNumberOfNewLeases
|
0 | ||
CY2024Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
68703 | |
CY2023Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
255044 | |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
445323 | ||
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
734393 | ||
CY2024Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
138819 | |
CY2023Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
155583 | |
us-gaap |
Variable Lease Cost
VariableLeaseCost
|
377525 | ||
us-gaap |
Variable Lease Cost
VariableLeaseCost
|
471879 | ||
CY2024Q3 | us-gaap |
Lease Cost
LeaseCost
|
207522 | |
CY2023Q3 | us-gaap |
Lease Cost
LeaseCost
|
410627 | |
us-gaap |
Lease Cost
LeaseCost
|
822848 | ||
us-gaap |
Lease Cost
LeaseCost
|
1206272 | ||
CY2024Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
196314 | |
CY2023Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
285122 | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
588943 | ||
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
845332 | ||
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
200240 | |
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
67401 | |
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
267641 | |
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
5508 | |
CY2024Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
262133 | |
CY2024Q3 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P0Y3M18D | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P1Y1M6D | |
CY2024Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.100 | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.100 | |
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
872892 | ||
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2024Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
CY2024Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.0179 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7812 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0417 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0357 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
CY2024Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1138115 | |
CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
887837 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3537517 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2616105 | ||
CY2024Q3 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
|
26 | |
CY2024Q3 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
|
0.80 | |
CY2024Q3 | us-gaap |
Restructuring Charges
RestructuringCharges
|
5000000.0 | |
CY2024Q3 | us-gaap |
Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
|
400000 | |
CY2024Q3 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
CY2024Q3 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
CY2024Q3 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2024Q3 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |